Perigon Wealth Management LLC bought a new stake in Grail, Inc. (NASDAQ:GRAL - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 14,917 shares of the company's stock, valued at approximately $260,000.
Other large investors have also recently made changes to their positions in the company. Douglas Lane & Associates LLC acquired a new position in Grail during the fourth quarter worth approximately $3,034,000. A. D. Beadell Investment Counsel Inc. purchased a new position in shares of Grail during the fourth quarter worth approximately $430,000. FNY Investment Advisers LLC acquired a new position in shares of Grail in the 4th quarter valued at $26,000. 180 Wealth Advisors LLC purchased a new stake in Grail in the 4th quarter valued at $1,681,000. Finally, B & T Capital Management DBA Alpha Capital Management acquired a new stake in Grail during the 4th quarter worth $387,000.
Grail Stock Performance
NASDAQ:GRAL traded down $1.40 during midday trading on Thursday, reaching $32.99. The stock had a trading volume of 1,551,916 shares, compared to its average volume of 1,126,059. Grail, Inc. has a 12-month low of $12.33 and a 12-month high of $35.67. The firm has a fifty day simple moving average of $21.12 and a two-hundred day simple moving average of $16.93.
Grail (NASDAQ:GRAL - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($3.94) earnings per share for the quarter. The firm had revenue of $28.65 million for the quarter. On average, sell-side analysts expect that Grail, Inc. will post -65.16 EPS for the current year.
Insiders Place Their Bets
In other Grail news, CFO Aaron Freidin sold 30,452 shares of the business's stock in a transaction on Monday, November 18th. The shares were sold at an average price of $14.02, for a total transaction of $426,937.04. Following the sale, the chief financial officer now directly owns 268,277 shares in the company, valued at approximately $3,761,243.54. The trade was a 10.19 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Analyst Upgrades and Downgrades
A number of research analysts have commented on GRAL shares. Morgan Stanley assumed coverage on shares of Grail in a research note on Wednesday, November 27th. They issued an "equal weight" rating and a $16.00 price objective on the stock. Wolfe Research assumed coverage on Grail in a research report on Friday, November 15th. They issued a "peer perform" rating on the stock. Finally, Guggenheim started coverage on Grail in a research report on Thursday, October 17th. They set a "neutral" rating for the company.
Check Out Our Latest Research Report on Grail
About Grail
(
Free Report)
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
Further Reading
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
